Demonstrating Feasibility of a Novel Diagnostic for Thrombosis Risk

该项目将展示将用于检测患者临床相关凝血缺陷的复杂分析方法应用于新兴的诊断传感器平台技术的可行性，该技术可用于改善许多高死亡率条件下的结果，尤其是在老龄化人口中常见的情况。血栓性疾病是死亡的首要原因，无论是作为疾病状态-心肌梗死或缺血性中风，还是作为大多数住院治疗的潜在并发症，包括分娩和常规手术。该项目将侧重于通过应用新的诊断技术展示明确的健康益处和有吸引力的商业案例，并将由Highland Biosciences提供，这是一家微型中小企业，利用强大的合作者网络，已被证明能够提供成功的TSB资助的项目。

This project will demonstrate the feasibility of applying a sophisticated analysis method for the detection of clinically relevant blood clotting defects in patients to an emerging diagnostic sensor platform technology that can be applied to improve outcomes in many high mortality conditions, particularly common amongst the ageing population. Thrombotic disorders are top causes for death, either as disease states – myocardial infarction or ischemic stroke, or as potential complications to most in-hospital treatments, including childbirth and routine surgery. The project will focus on demonstrating clear health benefits and attractive business case through the application of novel diagnostic techniques and will be delivered by Highland Biosciences, a micro SME that leverages a strong network of collaborators proven to deliver successful TSB funded projects.